XML 33 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current assets    
Cash $ 7,034,434 $ 17,538,272
Accounts receivable, net 538,587 822,351
Inventory, net 1,586,297 1,055,878
Prepaid expenses and other current assets 1,661,220 1,379,896
Total current assets 10,820,538 20,796,397
Restricted cash 5,690
Right-of-use assets 1,422,538 1,645,568
Property and equipment, net 345,087 204,217
Intangible assets, net 5,845,702 171,190
Goodwill 625,602
Other assets 18,334 18,334
Total Assets 19,083,491 22,835,705
Current liabilities    
Accounts payable 857,311 886,224
Accrued vacation 467,948 282,910
Accrued expenses and other current liabilities 1,511,856 1,510,990
R&D grant liability 780,682
Deferred revenue, current portion 116,161 135,063
Operating lease liability, current portion 240,645 134,091
Short term debt - related party 950,722
Warrant liabilities 788,100 1,686,200
Warrant liabilities - related party 2,834,547
Convertible debt - related party 60,197
Total current liabilities 8,608,169 4,635,479
Operating lease liability, net of current portion 1,301,919 1,542,564
Deferred revenue, net of current portion 49,056 92,928
Deferred tax liability 357,757
Total liabilities 10,316,901 6,270,971
Commitments and Contingencies (Note 13)
Qualigen Therapeutics, Inc. stockholders’ equity:    
Common stock, $0.001 par value; 225,000,000 shares authorized; 4,210,737 and 3,529,018 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively 42,110 35,290
Additional paid-in capital 110,528,050 101,274,073
Accumulated other comprehensive income 50,721
Accumulated deficit (103,385,172) (84,744,629)
Total Qualigen Therapeutics, Inc. stockholders’ equity 7,235,709 16,564,734
Noncontrolling interest 1,530,881
Total Stockholders’ Equity 8,766,590 16,564,734
Total Liabilities & Stockholders’ Equity $ 19,083,491 $ 22,835,705